Company: NDRA
Filing Date: 2025-10-28
Form Type: DEF 14A
Source: 0001654954-25-012254
Chunk: 27

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-28
Form: DEF 14A
Chunk 27
---
8, 2024)         |     |      |     |            |         |     |                      |         |     |     |                                            |   |     |                            |         |        |     |           |         |    |
| Irina Pestrikova                                       |     | 2024 |     |            | 126,298 |     |                      |       - |     |     |                                            | - |     |                            |       - |        |     |           | 126,298 |    |
| Former Senior Director, Finance (until August 8, 2024) |     | 2023 |     |            | 185,000 |     |                      |  29,724 |     |     |                                            | - |     |                            |       - |        |     |           | 214,724 |    |

______________

| (1) | The amounts shown in this column indicate the grant date fair value of option awards granted in the subject year computed in accordance with FASB ASC Topic 718. For additional information regarding the assumptions made in calculating these amounts, see Notes 2 and 8 to the financial statements included in Part II, Item 8 of this Annual Report. The shares underlying these option awards vest and become exercisable in three equal annual installments beginning on the first anniversary of their respective grant dates.                                                                                                                                                                                                                                                                         |
| (2) | Represents insurance premiums paid by the Company with respect to life insurance for the benefit of the named executive officer, unless footnoted otherwise.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| (3) | Prior to appointment as Chief Executive Officer, Mr. Tokman served on the Board and provided consulting services to the Company. As a Board member, in January 2024, he was awarded an annual option grant to purchase 600 shares with a per share exercise price of $1.59. This grant was subject to adjustment due to the one-for-fifty reverse stock split effected in August 2024 (the “August 2024 Reverse Stock Split”) and the one-for-thirty-five reverse stock split effected in November of 2024 (the “November 2024 Reverse Stock Split”). After adjustment, this grant is for 1 share with a per share exercise price of $2,782.50. The amount shown above, $954, indicates the grant date fair value of option awards granted in the subject year computed in accordance with FASB ASC Topic 718. |
| (4) | Board